Xylazine causes transient dose-related hyperglycemia and increased urine volumes in mares.
Xylazine given IV at doses of 0.5, 1.0, and 1.5 mg/kg to mares caused a significant (P less than 0.05) dose-related increase in serum glucose concentration and urine volume. Serum glucose concentrations as much as 150 mg/dl were recorded in mares after they were given the largest xylazine dose. The greatest urine volume, similar to changes in peak glucose concentration, always occurred during the first hour after dosing with xylazine and averaged 1.82, 3.93, and 5.68 ml/kg/hour after the 0.5-, 1.0-, and 1.5-mg/kg doses, respectively, were given. Urine osmolality and specific gravity were significantly (P less than 0.05) inversely related to urine volume. Although serum glucose concentrations were significantly increased above those measured after IV injection of saline solution, significant glucosuria was not detected.
D000698:Analgesia / Q000009:adverse effects / Q000662:veterinary*; D000818:Animals; D001786:Blood Glucose / Q000032:analysis; D002417:Cattle; D005260:Female; D006734:Horse Diseases / Q000139:chemically induced* / Q000652:urine; D006736:Horses / Q000652:urine*; D006943:Hyperglycemia / Q000139:chemically induced / Q000652:urine / Q000662:veterinary*; D013843:Thiazines / Q000494:pharmacology*; D014554:Urination / Q000187:drug effects; D014991:Xylazine / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*
D001786:Blood Glucose; D013843:Thiazines; D014991:Xylazine